Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

ILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. These materials will be sent free of charge to all stockholders of Millennium. In addition, all of these materials (and all other materials filed by Millennium with the U.S. Securities and Exchange Commission) will be available at no charge from the U.S. Securities and Exchange Commission through its website at http://www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the U.S. Securities and Exchange Commission by Millennium at http://www.millennium.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contacts:

Kyle Kuvalanka (investors) Karen Gobler (Media)

(617) 761-4734 (617) 444-1392


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan agreement with Celula, Inc., a diagnostic testing company ... enabling better patient care and improved outcomes.  Proceeds of ... and expand the commercialization of its products in the ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Fleur’s introduces ... combining the benefits of makeup, skin care and ... tinted cream is designed with specific complexion-correcting pigments ... even complexion and a healthy glow. Far more ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today ... Bulletin Board under,the Symbol LIXT. Commenting on this ... "We believe that being a publicly traded company will,enable ... to us as,a private company. Having access to the ...
... of Cervical ... Cancer Risk, ... it has entered into an agreement to exclusively,license the Human Papillomavirus ... measurement of high-risk HPV types using,DNA-based detection. Quantovir is believed to ...
... MGCD0103,s Orphan Drug, Designation for the Treatment of ... BOULDER, Colo. and MONTREAL, Sept. 24 ,Pharmion Corporation ... MYG) today,announced that the European Medicines Agency (EMEA) ... deacetylase (HDAC),inhibitor, as an Orphan Medicinal Product for ...
Cached Biology Technology:Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 2Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 3Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 4Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a mashup of monster movies, but palaeontologists have discovered evidence ... killing that took place 4 million years ago. ... careful, forensic-style analysis of bite marks on an otherwise well-preserved ... reconstructed the events that led to the death of the ...
... years of satellite data have found that the amount of ... the last three decades. Most of the increase has occurred ... increase in tropical regions. The new analysis shows, ... degrees a line that runs through central Texas in ...
... heart-healthy, essential omega-3 fatty acid is about to improve ... advance will move biotechnology onto the average consumer,s daily ... deliver positive environmental impacts and increase production to feed ... on Horizon , Recently, the U.S. Food and Drug ...
Cached Biology News:Jaws -- 4 million BC 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 3UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 4New biotech advance to add heart healthy omega-3s to US diet 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
Biology Products: